Chinese Biotechs Feel Chill Wind Of Hesitant Investors
Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.
You may also be interested in...
The US- and China-based biotech is expanding three oncology-centered clinical studies of two TGF-1/COX-2-targeted siRNA drug candidates from the US into China.
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.